Shaily Engineering sells 9 mil devices as GLP-1 demand rises

Shaily Engineering Plastics Limited [

] reported 9 million device sales in Q1 FY27, with GLP-1 pen platforms making up 50% to 60% of total volumes. Healthcare revenue grew 84% year-on-year, now contributing 51% of consolidated revenue. The core business transformation from traditional plastic molding to precision drug-delivery platforms is gaining speed. The company plans to expand annual pen capacity from ~55 million units in FY26 to ~75 million units by FY27, with 60% to 65% of upcoming capacity already tied to customer commitments. The market focuses heavily on current GLP-1 momentum, but the stock at ~48x FY28E earnings requires careful valuation discipline. Beyond injectables, execution timelines remain key. Key regulatory approvals for Semaglutide pens in Canada and Brazil offer growth visibility, but customer-led commercialisation schedules can cause quarter-to-quarter volume volatility. Higher raw material and freight costs may also compress short-term margins until price pass-throughs take effect by Q3 FY27. Long-term optionality depends on new platforms like semiconductor packaging trays, expected from Q4 FY27, and reusable auto-injectors planned for late FY27. Maintain an Equal-weight view on the stock given full valuations and execution risks. Disclosure: This post is for informational and educational purposes only and does not constitute financial or investment advice. The views expressed are based on research from publicly available information and internal analysis. Investors should consult a qualified financial advisor before making any investment decisions.